創維數字(000810.SZ):目前便攜式儲能、户用儲能在歐洲、非洲等區域已啟動銷售
格隆匯3月27日丨創維數字(000810.SZ)在投資者互動平台表示,公司旗下子公司創維儲能規劃三大業務方向,分別是便攜式儲能、户用儲能和工商業儲能。基於渠道及市場共享,目前便攜式儲能、户用儲能在歐洲、非洲等區域已啟動銷售。公司在户用儲能、小型標準液冷電池櫃等產品線有明確的產品規劃,除了硬件系統外,在BMS、EMS、用户端APP及後台系統方面,都有明確的產品規劃路徑和投入計劃,目前業務正在有序推進中。公司將基於技術積累、共享及發揮公司現有的渠道、市場、資源等優勢,重點投入國內外儲能行業市場,創新商業模式,提升產品的價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.